gatifloxacin has been researched along with Community Acquired Infection in 30 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 9.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "In this community-based safety surveillance study, the advanced-generation fluoroquinolone gatifloxacin was administered empirically to 15625 adults with community-acquired respiratory tract infections (RTIs), including 1562 clinically evaluable patients with community-acquired pneumonia (CAP) and 2391 with acute exacerbations of chronic bronchitis (AECB)." | 9.10 | Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. ( Andriole, VT; Jones, RN; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| "This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events." | 6.70 | Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. ( Medeiros, EA, 2002) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 6.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 5.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "In this community-based safety surveillance study, the advanced-generation fluoroquinolone gatifloxacin was administered empirically to 15625 adults with community-acquired respiratory tract infections (RTIs), including 1562 clinically evaluable patients with community-acquired pneumonia (CAP) and 2391 with acute exacerbations of chronic bronchitis (AECB)." | 5.10 | Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. ( Andriole, VT; Jones, RN; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| "We investigated the in vitro activity of AR-709, a novel diaminopyrimidine antibiotic currently in development for treatment of community-acquired upper and lower respiratory tract infections, against 151 Streptococcus pneumoniae strains from various European countries." | 3.74 | In vitro activity of AR-709 against Streptococcus pneumoniae. ( Jansen, WT; Milatovic, D; Verel, A; Verhoef, J, 2008) |
| " To consider the optimized administration method based on PK/PD theory for the elderly patients of gatifloxacin (GFLX), which was one of the oral respiratory quinolone antibacterial, Monte Carlo Simulation was conducted with community-acquired pneumonia and susceptibility data for Streptococcus pneumoniae (345 strains) collected by the second gatifloxacin surveillance study." | 3.74 | [The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation]. ( Fukushima, K; Hirakata, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, Y; Morinaga, Y; Nakamura, S; Seki, M; Tashiro, T; Yamamoto, Y; Yanagihara, K, 2007) |
| "A retrospective cohort study of hospitalized adult (> or =18 years) patients admitted with Community Acquired Pneumonia (CAP) or Acute Exacerbation of Chronic Bronchitis (AECB) in a US tertiary care hospital between 7/1/01 and 12/31/04 treated with gatifloxacin or ceftriaxone during hospital admission." | 3.74 | An evaluation of the effects of gatifloxacin on glucose homeostasis. ( Hatton, RC; Onyenwenyi, AJ; Winterstein, AG, 2008) |
| "IV gatifloxacin was stepped down to oral gatifloxacin in 90." | 2.71 | Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral st ( Badaró, R; Bumroongkit, C; Corrêa, JC; Dolmann, AL; Juárez Martínez, LG; Mayrinck, LR; Mera, JR; Tamez, R; Yang, JY, 2003) |
| "This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events." | 2.70 | Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. ( Medeiros, EA, 2002) |
| " The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia." | 2.70 | Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study. ( Carvalho, CR; Franca, SA, 2002) |
| "Gatifloxacin is an 8-methoxy fluoroquinolone with broad activity against respiratory tract pathogens, including those commonly associated with community-acquired pneumonia (CAP)." | 2.70 | Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. ( Gotfried, M; Gothelf, S; Nicholson, SC; Quinn, TC; Webb, CD; Wikler, MA, 2002) |
| "Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP)." | 2.70 | Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. ( Andes, DR; Ehrhardt, AF; Gothelf, S; Jones, RN; Mandell, LA; Nicholson, SC, 2002) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 2.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| " Gatifloxacin is safe and efficacious in adults of any age with community-acquired pneumonia, including the elderly up to 100 years old and patients with S." | 2.70 | Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. ( Gothelf, S; Naughton, BJ; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| "Since 2002, an epidemic of Clostridium difficile infections has occurred in southern Quebec, Canada." | 1.35 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. ( Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M, 2008) |
| " Previously described population pharmacokinetic models of gatifloxacin and levofloxacin administration in patients with serious CAP were utilised to simulate gatifloxacin and levofloxacin pharmacokinetics." | 1.33 | Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ( Hoban, DJ; Noreddin, AM; Zhanel, GG, 2005) |
| " Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients." | 1.32 | An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers. ( Nicodemo, AC, 2003) |
| "In vitro and in vivo models of infection suggest that the area under the concentration-time curve (AUC): minimum inhibitory concentration (MIC) ratio is the pharmacodynamic parameter that is most predictive of bactericidal activity for the fluoroquinolones." | 1.31 | Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. ( Ambrose, PG; Nicolau, DP, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (96.67) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jansen, WT | 1 |
| Verel, A | 1 |
| Verhoef, J | 1 |
| Milatovic, D | 1 |
| Labbé, AC | 1 |
| Poirier, L | 1 |
| Maccannell, D | 1 |
| Louie, T | 1 |
| Savoie, M | 1 |
| Béliveau, C | 1 |
| Laverdière, M | 1 |
| Pépin, J | 1 |
| Lui, KJ | 1 |
| Chang, KC | 1 |
| Medeiros, EA | 1 |
| Franca, SA | 1 |
| Carvalho, CR | 1 |
| Sher, LD | 1 |
| Poole, MD | 1 |
| Von Seggern, K | 1 |
| Wikler, MA | 2 |
| Nicholson, SC | 6 |
| Pankey, GA | 1 |
| Mandell, LA | 3 |
| Pfaller, MA | 1 |
| Jones, RN | 4 |
| Gotfried, M | 1 |
| Quinn, TC | 1 |
| Gothelf, S | 4 |
| Webb, CD | 4 |
| Andes, DR | 1 |
| Ehrhardt, AF | 1 |
| Andriole, VT | 1 |
| Wilson, WR | 2 |
| High, KP | 1 |
| Naughton, BJ | 1 |
| Stein, GE | 1 |
| Schooley, S | 1 |
| Tyrrell, KL | 1 |
| Citron, DM | 1 |
| Goldstein, EJ | 1 |
| Nicodemo, AC | 1 |
| Corrêa, JC | 2 |
| Badaró, R | 2 |
| Bumroongkit, C | 1 |
| Mera, JR | 1 |
| Dolmann, AL | 1 |
| Juárez Martínez, LG | 1 |
| Mayrinck, LR | 1 |
| Tamez, R | 1 |
| Yang, JY | 1 |
| Sethi, S | 1 |
| Lode, H | 2 |
| Aronkyto, T | 1 |
| Chuchalin, AG | 1 |
| Jaaskevi, M | 1 |
| Kahnovskii, I | 1 |
| Kleutgens, K | 2 |
| Martinez, FJ | 1 |
| Magyar, P | 1 |
| Muir, JF | 1 |
| Loos, U | 1 |
| Mendonça, JS | 1 |
| Yamaguti, A | 1 |
| Noreddin, AM | 1 |
| Hoban, DJ | 1 |
| Zhanel, GG | 1 |
| Okimoto, N | 1 |
| Kibayashi, T | 1 |
| Mimura, K | 1 |
| Yamato, K | 1 |
| Kurihara, T | 1 |
| Honda, Y | 1 |
| Osaki, K | 1 |
| Asaoka, N | 1 |
| Ohba, H | 1 |
| Dean, NC | 1 |
| Sperry, P | 1 |
| Wikler, M | 1 |
| Suchyta, MS | 1 |
| Hadlock, C | 1 |
| Yanagihara, K | 1 |
| Morinaga, Y | 1 |
| Fukushima, K | 1 |
| Nakamura, S | 1 |
| Kurihara, S | 1 |
| Seki, M | 1 |
| Izumikawa, K | 1 |
| Kakeya, H | 1 |
| Yamamoto, Y | 1 |
| Miyazaki, Y | 1 |
| Hirakata, Y | 1 |
| Tashiro, T | 1 |
| Kohno, S | 1 |
| Onyenwenyi, AJ | 1 |
| Winterstein, AG | 1 |
| Hatton, RC | 1 |
| Dresser, LD | 1 |
| Niederman, MS | 1 |
| Paladino, JA | 1 |
| Nicolau, DP | 1 |
| Ambrose, PG | 1 |
1 review available for gatifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Gatifloxacin in community-acquired respiratory tract infection.
Topics: Anti-Bacterial Agents; Biological Availability; Community-Acquired Infections; Fluoroquinolones; Gat | 2003 |
16 trials available for gatifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
Topics: Adult; Aged; Anti-Infective Agents; Central Nervous System Diseases; Community-Acquired Infections; | 2002 |
Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
Topics: Adult; Aged; Anti-Infective Agents; Brazil; Central Nervous System Diseases; Community-Acquired Infe | 2002 |
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Topics: Acute Disease; Aged; Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Dru | 2002 |
Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resis | 2002 |
Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Drug Admini | 2002 |
Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquired Infe | 2002 |
Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationsh | 2002 |
Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquire | 2002 |
Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquire | 2002 |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral st
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infect | 2003 |
A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquire | 2004 |
Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bact | 2004 |
Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Community-Acquired Infections; F | 2004 |
Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquired Infections; Female; Fluoroquinolo | 2005 |
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug | 2006 |
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxon | 2001 |
13 other studies available for gatifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
In vitro activity of AR-709 against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Europe; | 2008 |
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acqu | 2008 |
Notes on testing noninferiority in ordinal data under the parallel groups design.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Community-Acquired Infections; | 2013 |
Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
Topics: Anti-Infective Agents; Canada; Clinical Trials as Topic; Community-Acquired Infections; Dose-Respons | 2002 |
Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Community-Acquir | 2002 |
Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobi | 2003 |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Brazil; Community-Acquired Infection | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Comb | 2004 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Flu | 2005 |
[The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation].
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; | 2007 |
An evaluation of the effects of gatifloxacin on glucose homeostasis.
Topics: Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Bronchitis; Ceftriaxone; Cohort Studies; Communit | 2008 |
Gatifloxacin and moxifloxacin: two new fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gastrointesti | 2000 |
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Community-Acquired Infections; Fluoroqui | 2001 |